Date & Time: October 15, 2020 | 8:00 AM Pacific Daylight Time

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

In this webinar, Prof. Ed Schuuring of University Medical Center Groningen will report on a comparison study for the detection of mutations in plasma DNA of NSCLC patients using the Roche Cobas EGFR v2.0 Mutation Test, BioRad droplet digital PCR, and the Agena Bioscience UltraSEEK Lung Panel. Prof. Schuuring will discuss the detection sensitivity of clinically relevant markers across the platforms and will also highlight the relevance of pre-analytical quality and quantity assessment of cfDNA.

Dr. Alexander Sartori from Agena Bioscience will follow with an overview of the MALDI-TOF based MassARRAY System and available mutation panels for both tissue and plasma DNA in various cancers.

Prof. Dr. Ed Schuuring

Professor of Molecular Oncological Pathology, University Medical Center Groningen

Ed Schuuring studied Medical Biology at the University of Amsterdam (cum laude). In 1991 he received a staff position as a senior research scientist at the Department of Pathology at the Leiden University Medical Center. In 2001 Ed Schuuring continued his career at the Department of Pathology at the University Medical Center Groningen and was appointed as full professor in Molecular Oncological Pathology. His latest research interest is the detection and monitoring of tumor response and resistance to TKI treatment and immunotherapy in GIST and NSCLC. He is an active member of the Dutch Society of Pathology (chair of the section of Clinical, Molecular and Experimental Pathology), American Association of Cancer Research, the Association of Molecular Pathology, American Society of Clinical Oncology, European Society of Pathology, Dutch Society of Oncology, among others.

Dr. Alexander Sartori

Staff Scientist, Scientific Affairs, Agena Bioscience

Dr. Alexander Sartori is a chemist with a PhD from the University of Kiel in cell biology; Alexander has 20 years’ experience in the life science industry and broad technical and application skills with a focus on oncology. For the past 10 years he has managed various collaborations and international consortia. In 2015 Alexander joined Agena Bioscience and in his current position he leads Agena’s Scientific Affairs oncology activities globally with a focus on liquid biopsy.